Managing non-proportionality of hazards (PH) within TNT: A randomised phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced triple negative (TN) or brca1/2 breast cancer (BC)

Category Primary study
JournalTrials
Year 2015
This article has no abstract
Epistemonikos ID: 87e5d9e8a6a0826cdfa40728ccca1630adf95ac5
First added on: Feb 08, 2025